Skip to main content
Equibles
PLRX logo

PLRX · Pliant Therapeutics, Inc. · Metrics

Track PLRX — free

Use PLRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PLRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.91 0.00 (-0.07%)
Rebalance outlook locked
Market Cap
$56.50M
Shares
61.92M
Volume · Oct 21 33.32K Avg daily vol (3M) 421.65K

PLRX metrics

72 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.91
Market cap
$56.50M

Price action

20 metrics
Price change (1W)
-5.7%
Price change (30D)
-17.8%
Price change (3M)
-16.3%
Price change (6M)
-29.3%
Price change (YTD)
-25.2%
Price change (1Y)
-44.4%
Trailing year
Price change (5Y)
-94.8%
52-week high
$1.87
52-week low
$0.88
Change from 52-week high
-51.2%
Change from 52-week low
+3.2%
Annualized volatility
51.4%
Annualized volatility (3M)
47.5%
Beta
1.1
RSI (14D)
36.5
Price vs SMA 50
-15.6%
Price vs SMA 200
-22.6%
Avg volume (3M)
421,648
Relative volume
0.8
Average dollar volume
$453,583

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
61.92M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.4
reciprocal yield 264.0%
FCF yield
-127.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-165.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
306.4×
reciprocal yield 0.3%
EV / revenue historical average (5Y)
306.4×
reciprocal yield 0.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$97.48M
Net income (TTM)
−$92.29M
Trailing 12 months
Diluted EPS (TTM)
$-1.48
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.58
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.50
Operating cash flow per diluted share (TTM)
$-1.15
Free cash flow per diluted share (TTM)
$-1.15
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$1.04
Stock compensation per diluted share (TTM)
$0.31
Book value per share
$2.95

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-62.8%
Return on assets
-48.6%
Debt / equity
0.0
Current ratio
9.9
EBITDA (TTM)
—
Free cash flow (TTM)
−$70.89M
Quick ratio
9.9
Interest coverage
-102.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$158.10M
Latest balance sheet
Cash & equivalents
$24.88M
Total assets
$189.88M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$70.89M
Capital expenditures (TTM)
$0
R&D (TTM)
$63.83M
SG&A (TTM)
—
Stock compensation (TTM)
$19.38M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
86
13F filer change QoQ
-5
Institutional ownership
77.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
47.1%
Private-fund adviser ownership
40.1%
Active holders' share change QoQ
-2.9%
Holder tenure
7.8
Price vs estimated holder cost
-74.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.2%

Short interest

3 metrics
Short interest
6.9%
Latest settlement · 11.4 days to cover
Days to cover
11.4d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1746473 CUSIP 729139105 13F (30d) 2 filings 2 filers Visit website Investor relations